Moniyot-131 (Sodium Iodide (131i))

Sodium Iodide (131I), the active ingredient in Moniyot-131, is a radioisotope presented as a diagnostic radiopharmaceutical for oral use. It belongs to the therapeutic class of thyroid imaging and therapy agents and is selectively taken up by thyroid tissue, enabling both functional imaging and delivery of beta radiation for therapeutic ablation in hyperthyroidism and thyroid cancer.

GNH USA supplies Moniyot-131 as a licensed, GDP‑compliant international pharmaceutical supplier, sourcing the product from EU manufacturers and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moniyot-131 is employed in the thyroid pathway for both diagnostic imaging and therapeutic ablation.

- Thyroid imaging: Provides functional visualization of thyroid uptake, aiding assessment of gland activity and detection of nodular lesions. - Hyperthyroidism treatment: Delivers targeted beta radiation to overactive thyroid tissue, reducing hormone production in conditions such as Graves’ disease. - Thyroid cancer ablation: Used post‑thyroidectomy to eradicate residual thyroid cells, decreasing recurrence risk. - Thyroid nodule evaluation: Helps differentiate autonomous nodules from malignant lesions by measuring iodine uptake patterns.

Common Side Effects: - Nausea: mild gastrointestinal upset after ingestion. - Metallic taste: transient alteration in taste perception. - Salivary gland swelling: mild sialadenitis causing discomfort. - Dry mouth: reduced salivary flow.

Serious or Rare Side Effects: - Severe hypothyroidism: prolonged reduction in thyroid hormone requiring levothyroxine therapy. - Radiation thyroiditis: painful inflammation of the thyroid gland. - Bone marrow suppression: rare decrease in blood cell counts that may lead to anemia or infection.

Moniyot-131 should be used with caution and under professional supervision. - Pregnancy: avoid use unless benefits outweigh risks, as fetal thyroid may be affected. - Breastfeeding: discontinue nursing or stop medication, as iodine can be secreted in milk. - Concurrent antithyroid drugs: may reduce uptake, consider withholding before administration. - Renal impairment: adjust dose or monitor, as excretion is renal. - Thyroid function monitoring: assess hormone levels before and after treatment. - Store below 25°C: keep in original container, protect from moisture and light.

Moniyot-131 may interact with several medications and substances.

Major Interactions (Avoid): - Antithyroid medications (e.g., methimazole, propylthiouracil): block iodine uptake, reducing efficacy. - Lithium therapy: interferes with iodine transport, diminishing therapeutic effect. - High dietary iodine intake: competes with radioactive iodine, lowering glandular absorption.

Moderate Interactions (Monitor Closely): - Levothyroxine replacement: may require dose adjustment after ablation. - Beta‑blockers: may mask symptoms of thyroid storm, monitor clinical status. - Diuretics: can affect renal clearance of iodine, watch for accumulation.